The chemical biology of NAD regulation in axon degeneration
| dc.contributor.author | Icso, Janneke | |
| dc.contributor.author | Thompson, Paul R | |
| dc.date.accessioned | 2022-12-07T20:38:09Z | |
| dc.date.available | 2022-12-07T20:38:09Z | |
| dc.date.issued | 2022-07-01 | |
| dc.identifier.citation | Icso JD, Thompson PR. The chemical biology of NAD+ regulation in axon degeneration. Curr Opin Chem Biol. 2022 Aug;69:102176. doi: 10.1016/j.cbpa.2022.102176. Epub 2022 Jul 1. PMID: 35780654. | en_US |
| dc.identifier.eissn | 1879-0402 | |
| dc.identifier.doi | 10.1016/j.cbpa.2022.102176 | en_US |
| dc.identifier.pmid | 35780654 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14038/51410 | |
| dc.description.abstract | During axon degeneration, NAD+ levels are largely controlled by two enzymes: nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2) and sterile alpha and toll interleukin motif containing protein 1 (SARM1). NMNAT2, which catalyzes the formation of NAD+ from NMN and ATP, is actively degraded leading to decreased NAD+ levels. SARM1 activity further decreases the concentration of NAD+ by catalyzing its hydrolysis to form nicotinamide and a mixture of ADPR and cADPR. Notably, SARM1 knockout mice show decreased neurodegeneration in animal models of axon degeneration, highlighting the therapeutic potential of targeting this novel NAD+ hydrolase. This review discusses recent advances in the SARM1 field, including SARM1 structure, regulation, and catalysis as well as the identification of the first SARM1 inhibitors. | en_US |
| dc.language.iso | en | en_US |
| dc.relation.ispartof | Current Opinion in Chemical Biology | en_US |
| dc.relation.url | https://doi.org/10.1016/j.cbpa.2022.102176 | en_US |
| dc.rights | Copyright © 2022 Elsevier Ltd. All rights reserved. | en_US |
| dc.subject | Axon degeneration | en_US |
| dc.subject | Hydrolase | en_US |
| dc.subject | NAD(+) | en_US |
| dc.subject | Neuropathy | en_US |
| dc.subject | SARM1 | en_US |
| dc.subject | Wallerian degeneration | en_US |
| dc.title | The chemical biology of NAD regulation in axon degeneration | en_US |
| dc.type | Journal Article | en_US |
| dc.source.journaltitle | Current opinion in chemical biology | |
| dc.source.volume | 69 | |
| dc.source.beginpage | 102176 | |
| dc.source.endpage | ||
| dc.source.country | United States | |
| dc.source.country | United States | |
| dc.source.country | United States | |
| dc.source.country | England | |
| dc.identifier.journal | Current opinion in chemical biology | |
| atmire.contributor.authoremail | janneke.doedee@umassmed.edu | en_US |
| atmire.contributor.authoremail | Paul.thompson@umassmed.edu | en_US |
| dc.contributor.department | Thompson Lab | |
| dc.contributor.department | Biochemistry and Molecular Biotechnology | en_US |
| dc.contributor.department | Morningside Graduate School of Biomedical Sciences | en_US |